| Print
ImmunityBio (IBRX)
Common SharesThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Address
Forecast key dates
| Name | Key Date |
|---|---|
| ImmunityBio Inc Fourth Quarter Earnings Results for 2026 | 2027-02-23T00:00:00 |
| ImmunityBio Inc Annual Report for 2026 | 2027-02-23T00:00:00 |
| ImmunityBio Inc Third Quarter Earnings Results for 2026 | 2026-11-05T00:00:00 |
| ImmunityBio Inc Second Quarter Earnings Results for 2026 | 2026-07-24T00:00:00 |
| ImmunityBio Inc Annual General Meeting for 2026 | 2026-06-18T00:00:00 |
| ImmunityBio Inc First Quarter Earnings Results for 2026 | 2026-05-12T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| ImmunityBio Inc Fourth Quarter Earnings Results for 2025 | 2026-02-23T00:00:00 |
| ImmunityBio Inc Annual Report for 2025 | 2026-02-23T00:00:00 |
| Piper Sandler 37th Annual Healthcare Conference 2025 | 2025-12-02T00:00:00 |
| LUGPA 2025 Annual Meeting | 2025-11-06T00:00:00 |
| ImmunityBio Inc Third Quarter Earnings Results for 2025 | 2025-11-05T00:00:00 |
| BIO-Europe 2025 | 2025-11-03T00:00:00 |
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-08T00:00:00 |
| ImmunityBio Inc Second Quarter Earnings Results for 2025 | 2025-07-25T00:00:00 |
| ImmunityBio Inc Annual General Meeting for 2025 | 2025-06-18T00:00:00 |
| ImmunityBio Inc First Quarter Earnings Results for 2025 | 2025-05-12T00:00:00 |
| ImmunityBio Investor Day | 2025-04-15T00:00:00 |
| ImmunityBio Inc Fourth Quarter Earnings Results for 2024 | 2025-03-03T00:00:00 |
| ImmunityBio Inc Annual Report for 2024 | 2025-03-03T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2026 AJ Bell. All rights reserved.